IMVT-1402 Clinical Trials (2026): 8 Studies for Graves' Disease & Chronic Inflammatory Demyelinating Polyneuropathy

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

8 IMVT-1402 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Graves' Disease & Chronic Inflammatory Demyelinating Polyneuropathy) and 1,571 total planned enrollment. 1 Phase 3 IMVT-1402 trial and 7 Phase 2 are listed. 6 IMVT-1402 clinical trials are actively recruiting at 194 U.S. sites across 35 states. Most recent activity: NCT07032662 (May 2030).

Where to Participate: All IMVT-1402 Trial Sites in the U.S. (194 sites across 35 states)

Every actively recruiting IMVT-1402trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
ALSite Number - 1056Huntsville35801NCT07039916Map
ALSite Number - 1041Mobile36604NCT07039916Map
AZSite Number - 1017Phoenix85028NCT07039916Map
AZSite Number - 1036Phoenix85015NCT06727604Map
AZSite Number - 1025Scottsdale85251NCT07039916Map
AZSite Number - 1015Tucson85710NCT07018323Map
AZSite Number - 1042Tucson85718NCT07039916Map
AZSite Number - 1612Tucson85718NCT07032662Map
CASite Number - 1010Carlsbad92011NCT07039916Map
CASite Number - 1618Carlsbad92011NCT07032662Map
CASite Number -1014Concord94520NCT07018323Map
CASite Number - 1027Covina91722NCT06979531Map
CASite Number - 1007El Cajon91910NCT06979531Map
CASite Number - 1061Huntington Beach92647NCT06727604Map
CASite Number - 1028Irvine92697NCT07039916Map
CASite Number - 1001Los Angeles90033NCT06727604Map
CASite Number - 1023Los Angeles90033NCT07039916Map
CASite Number - 1047Los Angeles90095NCT06727604Map
CASite Number - 1016Menifee92586NCT06979531Map
CASite Number - 1062Orange92868NCT06727604Map
CASite Number - 1619Orange92868NCT07032662Map
CASite Number - 1029Rancho Mirage92270NCT07039916Map
CASite Number - 1607Rancho Mirage92270NCT07032662Map
CASite Number - 1046Sacramento95816NCT06727604Map
CASite Number - 1004San Francisco94143NCT07039916Map
CASite Number - 1034San Francisco94143NCT06727604Map
CASite Number -1608San Francisco94109NCT07032662Map
CASite Number - 1029Thousand Oaks91360NCT06979531Map
CASite Number - 1005Torrance90502NCT06727604Map
CASite Number - 1026Upland91786NCT06979531Map
COSite Number - 1013Aurora80045NCT07018323Map
COSite Number - 1013Englewood80113NCT06727604Map
COSite Number - 1014Fort Collins80528NCT06979531Map
COSite Number - 1027Fort Collins80528NCT07039916Map
COSite Number - 1626Parker80138NCT07032662Map
CTSite Number - 1001New Haven06510NCT07039916Map
CTSite Number - 1621New Haven06511NCT07032662Map
DESite Number - 1010Newark19713NCT06727604Map
DCSite Number - 1024Washington D.C.20010NCT07039916Map
DCSite Number - 1040Washington D.C.20010NCT06727604Map
DCSite Number - 1601Washington D.C.20037NCT07032662Map
DCSite Number - 1630Washington D.C.20010NCT07032662Map
FLSite Number - 1006Clearwater33761NCT07039916Map
FLSite Number - 1029Clearwater33756NCT06727604Map
FLSite Number - 1024Doral33166NCT07018323Map
FLSite Number - 1008Hialeah33016NCT07018323Map
FLSite Number - 1018Hollywood33024NCT06979531Map
FLSite Number - 1055Jacksonville32204-1177NCT06727604Map
FLSite Number - 1056Jacksonville32216NCT06727604Map
FLSite Number - 1021Jupiter33458NCT06979531Map
FLSite Number - 1603Maitland32751NCT07032662Map
FLSite Number - 1000Miami33143NCT07018323Map
FLSite Number - 1002Miami33143NCT06979531Map
FLSite Number - 1028Miami33136NCT06727604Map
FLSite Number - 1065Miami33186NCT06727604Map
FLSite Number - 1606Miami33136NCT07032662Map
FLSite Number - 1064Ocoee34761NCT06727604Map
FLSite Number - 1011Orlando32819NCT06727604Map
FLSite Number - 1037Ormond Beach32174NCT07039916Map
FLSite Number - 1617Ormond Beach32174NCT07032662Map
FLSite Number - 1002Port Charlotte33952NCT07039916Map
FLSite Number - 1016Port Charlotte33952NCT06727604Map
FLSite Number - 1620Port Charlotte33952NCT07032662Map
FLSite Number - 1050Rockledge32955NCT07039916Map
FLSite Number - 1633Rockledge32955NCT07032662Map
FLSite Number - 1004Tamarac33321NCT06979531Map
FLSite Number - 1007Tampa33612NCT07039916Map
FLSite Number - 1025Tampa33606NCT06979531Map
FLSite Number - 1012West Palm Beach33401NCT06727604Map
GASite Number - 1014Atlanta30329NCT07039916Map
GASite Number - 1038Atlanta30318NCT06727604Map
GASite Number - 1043Augusta30912NCT07039916Map
GASite Number - 1020Columbus31904NCT07018323Map
GASite Number - 1053Macon31210NCT06727604Map
GASite Number - 1020Stockbridge30281NCT06727604Map
ILSite Number - 1012Chicago60607NCT06979531Map
ILSite Number - 1033Orland Park60467NCT06979531Map
ILSite Number - 1054Schaumburg60173NCT07039916Map
INSite Number - 1027Indianapolis46202NCT06727604Map
KSSite Number - 1041Kansas City66210NCT06727604Map
KSSite Number - 1602Kansas City66205NCT07032662Map
KSSite Number - 1022Topeka66606NCT07018323Map
KYSite Number - 1045Bowling Green42101NCT06727604Map
KYSite Number - 1054Florence41042NCT06727604Map
KYSite Number - 1022Lexington40536-0284NCT07039916Map
KYSite Number - 1030Louisville40202NCT07018323Map
KYSite Number - 1032Nicholasville40356NCT07039916Map
KYSite Number - 1611Nicholasville40356NCT07032662Map
LASite Number - 1030Lake Charles77469NCT06979531Map
LASite Number - 1063Metairie70006NCT06727604Map
LASite Number - 1022New Orleans70112NCT06727604Map
LASite Number - 1028New Orleans70112NCT06979531Map
LASite Number - 1046New Orleans70121NCT07039916Map
LASite Number - 1048Shreveport71103NCT06727604Map
MDSite Number - 1023Baltimore21287NCT06727604Map
MASite Number - 1026Boston02114NCT06727604Map
MASite Number - 1623Boston02114NCT07032662Map
MASite Number - 1049Foxborough02035NCT07039916Map
MASite Number - 1625Worcester01655NCT07032662Map
MISite Number - 1026Detroit48201NCT07039916Map
MISite Number - 1629Detroit48201NCT07032662Map
MISite Number - 1005East Lansing48824NCT07039916Map
MISite Number - 1018Farmington Hills48334NCT06727604Map
MISite Number - 1069Flint48532NCT06727604Map
MNSite Number - 1008Rochester55905NCT06727604Map
MSSite Number - 1068Gulfport39501NCT06727604Map
MOSite Number - 1033Jefferson City65109NCT07018323Map
MOSite Number - 1004Kansas City64110NCT07018323Map
MOSite Number - 1019St Louis63110NCT07018323Map
NESite Number - 1017Omaha68105NCT06727604Map
NESite Number - 1018Omaha68198NCT07039916Map
NVSite Number - 1007Las Vegas89148NCT06727604Map
NVSite Number - 1634Las Vegas89106NCT07032662Map
NVSite Number - 1012Reno89511NCT07018323Map
NJSite Number - 1019Totowa07512NCT07039916Map
NYSite Number - 1032Canton13675NCT06979531Map
NYSite Number - 1032Long Island City11106NCT07018323Map
NYSite Number - 1006Mineola11501NCT06979531Map
NYSite Number - 1050Monroe10950NCT06727604Map
NYSite Number - 1027New Hyde Park11434NCT07018323Map
NYSite Number - 1009New York10022NCT07018323Map
NYSite Number - 1034New York10065NCT07039916Map
NYSite Number - 1036New York10021NCT07039916Map
NYSite Number - 1605New York10032NCT07032662Map
NYSite Number - 1627New York10065NCT07032662Map
NYSite Number - 1018Williamsville14221NCT07018323Map
NCSite Number - 1051Asheville28803NCT06727604Map
NCSite Number - 1010Chapel Hill27514NCT07018323Map
NCSite Number - 1020Chapel Hill27599NCT07039916Map
NCSite Number - 1013Durham27710NCT07039916Map
NCSite Number - 1026Hickory28601NCT07018323Map
NCSite Number - 1001Morehead City27577NCT07018323Map
NCSite Number - 1034Raleigh27612NCT07018323Map
NCSite Number - 1044Raleigh27607NCT07039916Map
NCSite Number - 1060Wilmington28401NCT06727604Map
OHSite Number - 1057Canton44718NCT06727604Map
OHSite Number - 1038Cincinnati45221NCT07039916Map
OKSite Number - 1007Oklahoma City73134NCT07018323Map
OKSite Number - 1045Oklahoma City73104NCT07039916Map
OKSite Number - 1011Yukon73099NCT07039916Map
OKSite Number - 1631Yukon73099NCT07032662Map
ORSite Number - 1031Eugene97477NCT07039916Map
ORSite Number - 1003Portland97035NCT06727604Map
PASite Number - 1013Philadelphia19104NCT06979531Map
PASite Number - 1616Philadelphia19107NCT07032662Map
PASite Number - 1043Pottstown19464NCT06727604Map
SCSite Number - 1015Charleston29486NCT07039916Map
SCSite Number - 1030Charleston29425NCT07039916Map
SCSite Number - 1015Summerville29485NCT06727604Map
TNSite Number - 1042Chattanooga37421NCT06727604Map
TNSite Number - 1015Jackson38305NCT06979531Map
TNSite Number - 1000Memphis38119NCT06979531Map
TNSite Number - 1017Memphis38119NCT07018323Map
TNSite Number - 1021Memphis38120NCT07039916Map
TNSite Number - 1049Nashville37212NCT06727604Map
TNSite Number - 1066Nashville37203NCT06727604Map
TXSite Number - 1001Allen75013NCT06979531Map
TXSite Number - 1020Amarillo79124NCT06979531Map
TXSite Number - 1022Arlington75231NCT06979531Map
TXSite Number - 1002Austin78731NCT06727604Map
TXSite Number - 1019Austin78745NCT06979531Map
TXSite Number - 1067Bellaire77401NCT06727604Map
TXSite Number - 1003Dallas75206NCT07039916Map
TXSite Number - 1019Dallas75208NCT06727604Map
TXSite Number - 1029Dallas75224NCT07018323Map
TXSite Number - 1047Denton76208NCT07039916Map
TXSite Number - 1002El Paso79935NCT07018323Map
TXSite Number - 1003Fort Worth76132NCT07018323Map
TXSite Number - 1024Grapevine76034NCT06979531Map
TXSite Number - 1010Houston77407NCT06979531Map
TXSite Number - 1011Houston77030NCT06979531Map
TXSite Number - 1028Houston77054NCT07018323Map
TXSite Number - 1031Houston77030NCT07018323Map
TXSite Number - 1071Houston77089NCT06727604Map
TXSite Number - 1622Houston77030NCT07032662Map
TXSite Number - 1021Irving75039NCT07018323Map
TXSite Number -1023Irving75031NCT07018323Map
TXSite Number - 1023Katy77494NCT06979531Map
TXSite Number - 1048Lubbock79414NCT07039916Map
TXSite Number - 1025McKinney75069NCT07018323Map
TXSite Number - 1004Mesquite75149NCT06727604Map
TXSite Number - 1009Round Rock78681NCT06727604Map
TXSite Number - 1011San Antonio78231NCT07018323Map
TXSite Number - 1014San Antonio78215NCT06727604Map
TXSite Number - 1031San Antonio78215NCT06979531Map
TXSite Number - 1052San Antonio78240NCT06727604Map
TXSite Number - 1628San Antonio78229NCT07032662Map
UTSite Number - 1030Salt Lake City84108NCT06727604Map
UTSite Number - 1070Sandy City84093NCT06727604Map
VASite Number - 1009Charlottesville22903NCT07039916Map
VASite Number - 1016Norfolk23510NCT07018323Map
VASite Number - 1040Richmond23298NCT07039916Map
WISite Number - 1035Greenfield53228NCT07039916Map
WISite Number - 1613Milwaukee53226NCT07032662Map

IMVT-1402 clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingenrolling by invitationTotal
P24217
P311

Recruiting IMVT-1402 clinical trials (6)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT07032662CIDPImeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)P2Chronic Inflammatory Demyelinating Polyneuropathy162Mar 2025
NCT07286006GDA Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)P2Graves' Disease372Jan 2026
NCT06979531Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease ActivityP2Primary Sjögren's Syndrome180Jun 2025
NCT07039916Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisP3Generalized Myasthenia Gravis231May 2025
NCT06727604A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseaseP2Graves' Disease240Dec 2024
NCT07018323A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseaseP2Graves' Disease210Jun 2025

IMVT-1402 clinical trials by indication

Graves' Disease (3)

NCTAcronymPhaseStatusTitle
NCT07286006GDP2enrolling by invitationA Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
NCT06727604P2recruitingA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323P2recruitingA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Primary Sjögren's Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT06979531P2recruitingEfficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

Generalized Myasthenia Gravis (1)

NCTAcronymPhaseStatusTitle
NCT07039916P3recruitingStudy to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Chronic Inflammatory Demyelinating Polyneuropathy (1)

NCTAcronymPhaseStatusTitle
NCT07032662CIDPP2recruitingImeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Subacute Cutaneous Lupus Erythematosus (1)

NCTAcronymPhaseStatusTitle
NCT06980805CLEP2active not recruitingA Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

Rheumatoid Arthritis (1)

NCTAcronymPhaseStatusTitle
NCT06754462P2active not recruitingA Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

IMVT-1402 pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
CIDPNCT07032662P2recruitingChronic Inflammatory Demyelinating Polyneuropathy162
GDNCT07286006P2enrolling by invitationGraves' Disease372
CLENCT06980805P2active not recruitingSubacute Cutaneous Lupus Erythematosus56

All IMVT-1402 trials (8)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07032662CIDPImeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)P2recruiting162Immunovant Sciences GmbHMar 2025
NCT07286006GDA Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)P2enrolling by invitation372Immunovant Sciences GmbHJan 2026
NCT06979531Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease ActivityP2recruiting180Immunovant Sciences GmbHJun 2025
NCT07039916Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisP3recruiting231Immunovant Sciences GmbHMay 2025
NCT06727604A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseaseP2recruiting240Immunovant Sciences GmbHDec 2024
NCT06754462A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid ArthritisP2active not recruiting120Immunovant Sciences GmbHJan 2025
NCT07018323A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseaseP2recruiting210Immunovant Sciences GmbHJun 2025
NCT06980805CLEA Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)P2active not recruiting56Immunovant Sciences GmbHFeb 2025

IMVT-1402 clinical trials: frequently asked questions

How many IMVT-1402 clinical trials are there?
8 IMVT-1402 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants.
Are IMVT-1402 clinical trials recruiting in 2026?
Yes — 6 IMVT-1402 trials are actively recruiting in 2026, with 194 U.S. sites across 35 states. See the recruiting trials and the per-state site list further down this page.
What conditions is IMVT-1402 being studied for?
IMVT-1402 is being studied for Graves' Disease, Chronic Inflammatory Demyelinating Polyneuropathy, Generalized Myasthenia Gravis, Chronic Cutaneous Lupus Erythematosus, Primary Sjögren's Syndrome and 2 more. The trials are grouped by indication on this page.
What phase is IMVT-1402 in?
IMVT-1402 clinical trials span 1 Phase 3, 7 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors IMVT-1402 clinical trials?
The lead sponsor across the most IMVT-1402 trials is Immunovant Sciences GmbH. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming IMVT-1402as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: